How and where to order Atomoxetine (Strattera) 10 mg, 18 mg, 25 mg, 40, 60 mg capsules or tablets online:
|Prices:||from $0.43 per pill
|Discount:||10% coupon: DFHDCC
|Forms:||10, 18, 25, 40, 60 mg tablets and capsules
|Type:||Atomoxetine brand, Strattera generic
|Payment:||Visa, MasterCard, AmEx, ACH, Bitcoin
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Atomoxetine (trade names include Strattera, Abretia, Attentin, Attentrol, Axepta) is a selective norepinephrine reuptake inhibitor (SNRI) from centrally acting sympathomimetics pharmacological group. This medication is used to treat attention deficit hyperactivity disorder (ADHD) in children 6 years or older and adults; for the treatment of people with major depression, fibromyalgia, social anxiety disorder. Atomoxetine increases certain endogeneous chemicals (eg, norepinephrine) in the brain, thats why it is not a stimulant like other drugs for ADHD. The advantage of Atomoxetine HCL over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in children and adults. Strattera can improve attention span, concentration, and emotional control. This medicine also reduces restless or overactive behavior.
Atomoxetine Hydrochloride medications
Strattera prescribing information
Strattera patient information
Strattera medication guide
Lithium Carbonate (Lithobid)
Pharmacological and medical categories:
CNS drugs and agents for ADHD
Central nervous system agents
Selective norepinephrine (noradrenaline) reuptake inhibitors (SNRI)
N - Nervous system
N06 - Psychoanaleptics
N06B - Psychostimulants, agents used for adhd and nootropics
N06BA - Centrally acting sympathomimetics
N06BA09 - Atomoxetine
Major depressive disorder, single episode - F32
Major depressive disorder, recurrent - F33
Phobic anxiety disorders - F40
Attention-deficit hyperactivity disorders (Hyperkinetic disorders) - F90
Fibromyalgia - M79.7
Indications and usage:
Strattera (Atomoxetine Hydrochloride) is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Dosage and administration:
Initial, Target and Maximum Daily Dose for acute and maintenance/extended treatment:
||Initial Daily Dose
||Target Total Daily Dose
||Maximum Total Daily Dose
|Children and adolescents up to 70 kg
|Children and adolescents over 70kg and adults
Dosing adjustment - Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs).
No fatal overdoses occurred in clinical trials with atomoxetine. There is limited clinical trial experience with Strattera overdose. During postmarketing, there have been fatalities reported involving a mixed ingestion overdose of this medication and at least one other drug. There have been no reports of death involving overdose of atomoxetine alone, including intentional overdoses at amounts up to 1400 mg. In some cases of overdose involving Strattera, seizures have been reported. The most commonly reported symptoms accompanying acute and chronic overdoses of this drug were somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms. Signs and symptoms consistent with mild to moderate sympathetic nervous system activation (e.g., mydriasis, tachycardia, dry mouth) have also been observed. Less commonly, there have been reports of QT prolongation and mental changes, including disorientation and hallucinations.
Management of overdose
An airway should be established. Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be indicated if performed soon after ingestion. Activated charcoal may be useful in limiting absorption. Because Strattera (Atomoxetine) is highly protein-bound, dialysis is not likely to be useful in the treatment of overdose.
Dosage forms and strengths:
Each Strattera capsule contains Atomoxetine HCl equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of Atomoxetine.
Hypersensitivity to atomoxetine or other constituents of product.
Strattera use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations.
Narrow angle glaucoma.
Pheochromocytoma or history of pheochromocytoma.
Severe cardiovascular disorders that might deteriorate with clinically important increases in HR and BP.
Warnings and precautions:
Suicidal Ideation - Monitor for suicidality, clinical worsening, and unusual changes in behavior.
Severe Liver Injury - Should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury.
Serious Cardiovascular Events - Sudden death, stroke and myocardial infarction have been reported in association with atomoxetine treatment. Patients should have a careful history and physical exam to assess for presence of cardiovascular disease. Strattera generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to its noradrenergic effects. Consideration should be given to not using Strattera in adults with clinically significant cardiac abnormalities.
Emergent Cardiovascular Symptoms - Patients should undergo prompt cardiac evaluation.
Effects on Blood Pressure and Heart Rate - Increase in blood pressure and heart rate; orthostasis and syncope may occur. Use with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease.
Emergent Psychotic or Manic Symptoms - Consider discontinuing treatment if such new symptoms occur.
Bipolar Disorder - Screen patients to avoid possible induction of a mixed/manic episode.
Aggressive behavior or hostility shouldbe monitored.
Possible allergic reactions, including anaphylactic reactions, angioneurotic edema, urticaria, and rash.
Effects on Urine Outflow - Urinary hesitancy and retention may occur.
Priapism - Prompt medical attention is required in the event of suspected priapism.
Growth - Height and weight should be monitored in pediatric patients.
Concomitant Use of Potent CYP2D6 Inhibitors or Use in patients known to be CYP2D6 PMs - Dose adjustment of Strattera may be necessary.
Adverse reactions, side effects:
Most common adverse reactions of Strattera (Atomoxetine HCl) capsules ( >= 5% and at least twice the incidence of placebo patients):
Child and adolescent clinical trials - nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence.
Adult clinical trials - constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation.
To report suspected adverse reactions, contact Eli Lilly and Company or U.S. FDA
Monoamine Oxidase Inhibitors.
CYP2D6 Inhibitors - concomitant use may increase atomoxetine steady-state plasma concentrations in EMs.
Antihypertensive drugs and pressor agents - possible effects on blood pressure.
Albuterol (or other beta-2 agonists) - action of albuterol (salbutamol) on cardiovascular system can bepotentiated.
Use in specific populations:
Pregnancy and lactation - pregnant or nursing women should not use unless potential benefit justifies potential risk to fetus or infant.
Hepatic insufficiency - increased exposure (AUC) to atomoxetine than with normal subjects in EM subjects with moderate (Child-Pugh Class B) (2-fold increase) and severe (Child-Pugh Class C) (4-fold increase).
Renal insufficiency - higher systemic exposure to atomoxetine than healthy subjects for EM subjects with end stage renal disease - no difference when exposure corrected for mg/kg dose.
Patients with concomitant illness - does not worsen tics in patients with ADHD and comorbid Tourette's disorder.
Patients with concomitant illness - does not worsen anxiety in patients with ADHD and comorbid anxiety disorders.
B3 - Australia
C - United States (Risk cannot be ruled out)
Salts and other forms:
Synonyms, international and chemical names:
Benzenepropanamine, N-Methyl-Gamma-(2-Methylphenoxy)-, (GammaR)-
Brands, generics, trade names:
Abretia - Roemmers Laboratorios
Apo-Atomoxetine - Apotex
Atomox Apex - Multi-Apex Pharma
Atomoxetin - Actavis, Sandoz
Atomoxetina - Teva, Zentiva
Atomoxetine - Dr. Reddy's Laboratories, Mylan, Sandoz, Teva
Attentin - Ranbaxy, Solus Pharmaceuticals
Attentrol - Sun Pharmaceutical Industries
Axepta - Intas Pharmaceuticals
Hypercon - Consern Pharma
Novo-Atomoxetine - Novopharm
Strattera - Eli Lilly
Here is a list of popular medications containing atomoxetine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Capsules; Oral; Atomoxetine Hydrochloride 10 mgCapsules; Oral; Atomoxetine Hydrochloride 18 mgCapsules; Oral; Atomoxetine Hydrochloride 25 mgCapsules; Oral; Atomoxetine Hydrochloride 40 mgCapsules; Oral; Atomoxetine Hydrochloride 60 mgCapsules; Oral; Atomoxetine Hydrochloride 80 mgCapsules; Oral; Atomoxetine Hydrochloride 100 mg
||Capsules; Oral; Atomoxetine Hydrochloride 10 mgCapsules; Oral; Atomoxetine Hydrochloride 18 mgCapsules; Oral; Atomoxetine Hydrochloride 25 mgTablets; Oral; Atomoxetine Hydrochloride 10 mg
||Sun Pharmaceutical Industries
||Tablets; Oral; Atomoxetine Hydrochloride 10 mgTablets; Oral; Atomoxetine Hydrochloride 18 mgTablets; Oral; Atomoxetine Hydrochloride 25 mgTablets; Oral; Atomoxetine Hydrochloride 40 mg
||Capsules; Oral; Atomoxetine Hydrochloride 5 mgCapsules; Oral; Atomoxetine Hydrochloride 10 mgCapsules; Oral; Atomoxetine Hydrochloride 18 mgCapsules; Oral; Atomoxetine Hydrochloride 25 mgCapsules; Oral; Atomoxetine Hydrochloride 40 mgCapsules; Oral; Atomoxetine Hydrochloride 60 mgCapsules; Oral; Atomoxetine Hydrochloride 80 mgCapsules; Oral; Atomoxetine Hydrochloride 100 mgSolution; Oral; Atomoxetine Hydrochloride 4 mg / ml
||Eli LillyAgencia Lei Va HongDKSHFour StarY.C. WooZuellig Pharma
Atomoxetine main article on Wikipedia: https://en.wikipedia.org/wiki/Atomoxetine
Atomoxetine compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Atomoxetine
Atomoxetine Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Atomoxetine-hydrochloride
Atomoxetine on DrugBank: https://www.drugbank.ca/drugs/DB00289
Atomoxetine Hydrochloride on DrugBank: https://www.drugbank.ca/salts/DBSALT001207
Atomoxetine FAQ on MedlinePlus: https://medlineplus.gov/druginfo/meds/a603013.html
Atomoxetine Hydrochloride capsules drug label info on DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup...
Strattera (Atomoxetine HCl) capsules drug label info on DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup...
Atomoxetine international drug names on Drugs.com: https://www.drugs.com/international/atomoxetine.html
Atomoxetine for sale on Pharma Doctor: https://pharma-doctor.com/atomoxetine.html
Atomoxetine containing drugs on Drugs-About.com: https://drugs-about.com/ing/atomoxetine.html
Strattera (Atomoxetine Hydrochloride) capsules official prescribing information and medication guide from the U.S. FDA (Revised 06/2009): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Strattera (Atomoxetine Hydrochloride) capsules prescribing information from Eli Lilly pharmaceutical company: https://pi.lilly.com/us/strattera-pi.pdf
Strattera (Atomoxetine Hydrochloride) capsules medication guide from Eli Lilly pharmaceutical company: http://uspl.lilly.com/strattera/strattera.html#mg
Strattera (Atomoxetine Hydrochloride) capsules product monograph from Eli Lilly pharmaceutical company: http://pi.lilly.com/ca/strattera-ca-pm.pdf
Strattera (Atomoxetine HCl) 10, 18, 25, 40, 60, 80 and 100 mg hard capsules package information leaflet from Medicines.org.uk: https://www.medicines.org.uk/emc/files/pil.5531.pdf
Attentrol (Atomoxetine Hydrochloride, Strattera generic by Sun Pharma) capsules product information from Practo: https://www.practo.com/medicine-info/attentrol-10-capsule-46964
Updated: September 2020
Reviewed: September 2020
Copyright © Alpha Behavioral Care, P.A.